Antipsychotic Drugs Market Size, Share & Trends Report

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-408-6
  • Number of Pages: 90
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Market Segmentation

  • Antipsychotic Drugs Class Type Outlook (Revenue, USD Million; 2014 - 2025)
    • First Generation
      • Haldo
      • Navane
      • Others
    • Second Generation
      • Invega
      • Latuda
      • Seroquel
      • Risperdal
      • Zyprexa
      • Geodon
      • Others
    • Third generation
      • Abilify
  • Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
    • Schizophrenia
    • Bipolar disorders
    • Dementia
    • Unipolar Depression
    • Others
  • Antipsychotic Drugs Regional Outlook (Revenue, USD Million; 2014 - 2025)
    • North America
      • U.S.
        • U.S. Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • U.S. Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
      • Canada
        • Canada Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
      • Canada Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
        • Schizophrenia
        • Bipolar disorders
        • Dementia
        • Unipolar Depression
        • Others
    • Europe
      • UK
        • U.K. Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • U.K. Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
      • Germany
        • Germany Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • Germany Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
    • Asia Pacific
      • Japan
        • Japan Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • Japan Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
      • China
        • China Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • China Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
    • Latin America
      • Brazil
        • Brazil Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • Brazil Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
      • Mexico
        • Mexico Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
        • Mexico Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
          • Schizophrenia
          • Bipolar disorders
          • Dementia
          • Unipolar Depression
          • Others
    • MEA
      • South Africa
        • South Africa Antipsychotic Drugs Classes Outlook (Revenue, USD Million; 2014 - 2025)
          • First Generation
            • Haldo
            • Navane
            • Others
          • Second Generation
            • Invega
            • Latuda
            • Seroquel
            • Risperdal
            • Zyprexa
            • Geodon
            • Others
          • Third generation
            • Abilify
      • South Africa Antipsychotic Drugs Application Outlook (Revenue, USD Million; 2014 - 2025)
        • Schizophrenia
        • Bipolar disorders
        • Dementia
        • Unipolar Depression
        • Others

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2014 to 2025
  • Market estimates and forecast for product segments up to 2025
  • Regional market size and forecast for product segments up to 2025
  • Market estimates and forecast for application segments up to 2025
  • Regional market size and forecast for application segments up to 2025
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon